Watch Dr. David Lui interview Professor Sheila K. Krishnadath discuss the recent approval of a research project focusing on biomarkers. The grant is the culmination of many years of research looking at biomarkers as a means of making clinical decisions for managing Barrett’s esophagus. Up until now this research has been conducted solely in the Netherlands and through the grant they now have the opportunity to undertake multicenter studies in several high-risk areas of the world, implementing biomarkers in clinical decision making. Through this research the team hopes to identify which patients are high risk and provide a method for tracking their progression.
GOAL ENDEAVOR CONSORTIUM: The ambition of the ENDEAVOR consortium is to implement an innovative risk stratification method, which encompasses minimally invasive cell collection supplemented by single cell genomic analysis to address this specific need. Taking into account patient characteristics, gender dimensions, an optimal model will be tested in a randomized controlled prospective trial. Future implementation of this method will reduce health care costs, increase quality of life and satisfaction of health care providers. This action is part of the Cancer Mission cluster of projects on Diagnostics and Treatment (diagnostics).
